Kornimate/medical-research-clean huggingface dataset:
a collection of clinical and epidemiologic data combined with tissue and blood from patients with a diagnosis of neuroendocrine tumors

Conditions: Gastric Cancer; Pancreatic Cancer

Summary: the purpose of this study is to establish a neuroendocrine tumor registry. a registry is a collection of information. to create this registry, the investigators would like to get information, blood and tumor samples from people with neuroendocrine tumors. by collecting this information and material, the investigators are hoping to learn more about the genetic causes of neuroendocrine tumors. all of this will help us to better understand neuroendocrine cancer, so the investigators can find better ways to treat and diagnose this disease. dna will be taken from the blood samples and will be used in future studies. this will be an important resource from which the investigators can study genes that may be related to a higher risk of neuroendocrine tumors. the information collected will include medical information, family history of cancer and your answers to questions about how the cancer affects quality of life.


Eligibility criteria:
inclusion criteria: * diagnosis of gastroenteropancreatic neuroendocrine tumors or neuroendocrine tumors of unknown primary * willing to donate blood samples * \>= 18years old * patients may have received prior hormonal therapy, cytotoxic therapy, irradiation, immunotherapy or surgical therapy exclusion criteria: * have any condition, which in the opinion of the primary mskcc clinician or investigators precludes their ability to provide informed consent

Keywords: pancreas stomach questionnaire 08-105
acupuncture effect on inflammatory markers in pediatric otitis media with effusion: a pilot study

Conditions: Otitis Media With Effusion

Summary: objective: to evaluate acupunctures effect on inflammatory markers in pediatric otitis media with effusion methods: 100 children with otitis media with effusion (ome) diagnosis, who are in watchful waiting for 3 month, will be randomized in two groups: acupuncture and control. 50 children in the acupuncture group will receive standard treatment combined with acupuncture for 3 months. 50 children in the control group will receive standard treatment only, for the same time period. after 3 months, both groups will be reassessed for ome. children with no improvement from both groups will be assigned for tympanostomy. data collection: in children undergoing tympanostomy, middle ear effusion (mee) will be collected, analyzed and evaluated for group differences.


Eligibility criteria:
inclusion criteria: * otherwise healthy children ages 2-8 years * autoscopic ome diagnosis * tympanometry type b * conductive hearing impairment of 30 decibel or more * who are at watchful waiting treatment for 3 months * signed parental consent. exclusion criteria: * lack of parental consent * known coagulopathy * past tympanostomy * regular intake of steroids or cytotoxic drugs

Keywords: otitis media with effusion acupuncture inflammatory markers
acute normovolemic hemodilution in high risk cardiac surgery patients.

Conditions: C.Surgical Procedure; Cardiac

Summary: transfusions are one of the most overused treatments in modern medicine, and saving blood is one important issue all around the world. cardiac surgery makes up a large percentage of the overall blood components consumption in surgery. acute normovolemic hemo-dilution (anh) is a well-known strategy which has been used for years without the support of high quality evidence based medicine to improve post-cardiopulmonary bypass coagulation and reduce red blood cells (rbc) transfusion. we designed a multicenter randomized controlled trial to investigate the effect of anh in reducing the number of cardiac surgery patients receiving rbc transfusions during hospital stay. we will randomize 2000 patients to have sufficient power to demonstrate a 20% relative and 7% absolute risk reduction in the number of patients' rbc transfusion. if the results of the study will confirm our hypothesis, this will have a great impact on blood management in cardiac operating room.


Eligibility criteria:
inclusion criteria: * signed informed consent * any cardiac surgical intervention on cpb * elective surgery exclusion criteria: * medical decision (e.g.: planned pre-cpb anh considered undeniable for ethical reasons or not applicable for safety issues) * unstable coronary artery disease: recent (\ 70%) left main coronary artery stenosis * critical preoperative state (ventricular tachycardia or ventricular fibrillation or aborted sudden death, preoperative cardiac massage, preoperative ventilation before anesthetic room, hemodynamic instability, preoperative inotropes or iabp, preoperative severe acute renal failure (anuria or oliguria \<10ml/hr.) * emergency surgery * pregnancy * unfeasibility to withdraw ≥ 650 ml without inducing hemodynamic instability * unfeasibility to withdraw ≥ 650 ml without inducing pre-cpb anemia (htc \<30%) * unfeasibility to withdraw ≥ 650 ml without inducing low htc during cpb (htc \<24%)

Keywords: tissue organ and systemic injury responses to surgery trauma burn sepsis hemorrhage ischemia- reperfusion resuscitation including integrating pathways and signals cardiac surgery transfusion
effect of different inspired oxygen concentrations on intraoperative recruitment outcomes in patients undergoing abdominal surgery

Conditions: Pulmonary Atelectasis, Postoperative

Summary: this study intends to evaluate the effect of different inhaled oxygen concentrations on the effect of lung recruitment in patients undergoing abdominal surgery. during perioperative mechanical ventilation, higher fio2 is usually given to prevent the occurrence of hypoxemia, but there are no conclusions about the setting of optimal fio2 during surgery. dynamic pulmonary compliance enables real-time monitoring of alveolar changes and is used to assess pulmonary function in intraoperative patients. the value of compliance represents the number of air-containing alveoli; the more alveoli are trapped, the less air-containing tissue there is and the lower the compliance. lung recruitment, as part of a lung-protective ventilation strategy, is effective in opening alveoli and improving oxygenation. this single-center, randomized controlled trial will explore the optimal inspired oxygen concentration that allows patients to benefit from lung recruitment and the duration of improvement in lung compliance after lung recruitment.


Eligibility criteria:
inclusion criteria: * asa physical status classification: i or ii. * adults aged 18 to 64 years, regardless of gender. * bmi between 18 kg/m² and 25 kg/m². * patients undergoing elective abdominal surgery under general anesthesia. * patients with estimated operating time ≥1.5h and intraoperative bleeding ≤500ml. * patients who have provided written informed consent after understanding the study purpose, procedures, and potential risks. exclusion criteria: * previous thoracic surgery. * chest x-ray or ct suggestive of pneumothorax or alveoli. * lung disease: chronic bronchitis, asthma, moderate to severe obstructive ventilatory dysfunction. * preoperative pulse oxygen saturation (spo2) \<90% on breathing air or spo2 \<95% on oxygen. * contraindications to lung reanimation: high intracranial pressure, hypovolemic shock, right heart failure. * severe heart disease (new york heart association, nyha class iii or iv. * acute coronary syndrome or sustained ventricular tachyarrhythmia). * participation in other interventional studies or refusal of enrollment.

Keywords: inhaled oxygen concentration lung recruitment
standardized diagnosis and treatment of endocrine hypertension

Conditions: Endocrine Hypertension

Summary: cases of endocrine hypertension or primary hypertension who have signed informed consent will be collected. patients with endocrine hypertension will be divided into surgical treatment group and drug treatment group according to actual treatment situation. a database will be established for all patients. the investigators will comprehensively evaluate the general conditions, past medical history, metabolic and biochemical indicators, psychological status, cardiovascular risk factors. all the patients will be followed up for 12 months at baseline, 6 months and 12 months. clinical data and specimen will be collected.

the investigators will collect 100 patients with secretory hypertension and 100 patients with essential hypertension. patients with endocrine hypertension will be divided into surgical treatment group and drug treatment group according to actual treatment situation. resected specimens from surgical patients will be used for immunohistochemistry and western blot. a database will be established for all patients to assess their general situation, past medical history, metabolic and biochemical indicators, psychological status, cardiovascular risk factors, etc. the investigators expect to find more accurate screening indicators from blood and urine specimens. all the patients will be followed up for 12 months at baseline, 6 months and 12 months. blood pressure, degree of atherosclerosis, biochemical markers, hormone levels and cardiac function indicators will be measured at three time points.

Eligibility criteria:
inclusion criteria: age≥18 years exclusion criteria: 1. myocardial infarction 2. congestive heart failure 3. stroke
effect of lifitegrast 5% on tear film markers

Conditions: Dry Eye; Dry Eye Syndromes; Dry Eyes Chronic

Summary: the purpose of this study is to assess the duration of time (in weeks) for improvement in objective dry eye markers for people who are placed on lifitegrast 0.5% (xiidra®), an fda-approved therapy for dry eyes.


Eligibility criteria:
inclusion criteria: * signs or symptoms of dry eye disease * 18 years or older * abnormal mmp9 (positive as read by 2 blinded investigators with both in agreement) and/or abnormal tear osmolarity (greater than or equal to 308 or an inter-eye difference \>=8 mosm/ml) exclusion criteria: * active eye infection. patients with blepharitis may be enrolled. * any eye drop that was instilled within 2 hours of the baseline eye exam * current contact lens wearer. subjects who have not worn contact lenses 30 days prior to baseline and have no intention to wear cls during the study duration may enroll. * history of ocular herpes simplex * active episcleritis, scleritis, iritis or uveitis * active keratitis secondary to any etiology other than dry eyes * history of refractive surgery (lasik or prk) or penetrating corneal transplant (pk) * uses eye drops (ex. glaucoma or allergy drops) for indications other than dry eyes * active allergic conjunctivitis * current use of punctal plugs or anticipation of use during the study * use of topical ophthalmic steroids within 14 days of the baseline visit or anticipated use during the study * use of lifitegrast 5% or restasis within 30 days of the baseline visit. * allergy to lifitegrast 5%

Keywords: dry eye lifitegrast xiidra
iron dextran versus oral iron for treating iron deficiency anemia in pregnant women

Conditions: Anemia

Summary: iron deficiency is the most prevalent nutritional deficiency and the most common cause of anemia .it is characterized by a defect in hemoglobin synthesis, resulting in red blood cells that are abnormally small (microcytic) and contain a decreased amount of hemoglobin (hypochromic).


Eligibility criteria:
inclusion criteria: * hemoglobin \< 10 g/dl * gestational age between 14-28 weeks. * willingness to participate and signing the informed consent form. exclusion criteria: * iron overload or disturbances in utilization of iron * decompensated liver cirrhosis and active hepatitis * active acute or chronic infections * history of multiple allergies * known hypersensitivity to parenteral iron or any recipients in the investigation drug products * erythropoietin treatment within 8 weeks prior to the screening visit * other iron treatment or blood transfusion within 4 weeks prior to the screening visit * planned elective surgery during the study.
fecal helicobacter pylori gene detection for gastric cancer

Conditions: Gastric Adenocarcinoma; Helicobacter Pylori

Summary: this is a prospective, multicenter, cross-sectional study. the efficacy of fecal h. pylori gastric cancer susceptibility testing in predicting gastric cancer was evaluated by comparing fecal h. pylori gastric cancer susceptibility testing with the "gold standard" imaging tests, such as ct, gastroscopy, and/or pathology, in the enrolled population.

primary study objective: to assess the sensitivity and specificity of fecal h. pylori gastric cancer susceptibility locus-based testing applied to predict gastric cancer. secondary research objectives: 1. the accuracy, kappa value, area under the roc curve, positive likelihood ratio, negative likelihood ratio, positive predictive value, negative predictive value of fecal h. pylori gastric cancer susceptibility locus test applied to predict gastric cancer; 2. whether the predictive ability is significantly higher than that of the conventional tumor markers, such as ca19-9, cea, and ca72-4, etc.; and 3. combined with fecal methylation detection predictive ability assessment. the "fecal h. pylori-based gastric cancer susceptibility locus test" was compared with the "gold standard" ct, gastroscopy and/or pathology, and the results were analyzed for consistency.

Eligibility criteria:
inclusion criteria: 1. be ≥40 years of age, male or female. 2. have or will have gastroscopy and/or pathology results. 3. have no contraindications to endoscopy and be able to cooperate with endoscopy. 4. patients must be able to fully understand the informed consent form and be able to sign the informed consent form in person. exclusion criteria: 1. severe cardiac, hepatic, or renal insufficiency, or psychiatric disorders. 2. a previous history of upper gastrointestinal malignancy. 3. women during pregnancy. 4. those whose pathology is not clear. 5. those with unsatisfactory sample retention (e.g., too small a sample size).
a "window trial" on boswellia for breast cancer primary tumors

Conditions: Breast Cancer

Summary: the purpose of this study is to determine whether oral administration of boswellia causes biological changes in primary tumors of breast cancer patients.

to determine whether oral administration of boswellia serrata causes biological changes related to angiogenesis (cd31), apoptosis (dna fragmentation), and cell proliferation (ki67) in primary tumors of breast cancer patients.

Eligibility criteria:
inclusion criteria: * histologically confirmed ductal carcinoma in situ (dcis) or invasive breast cancer (stages i, ii, or iii) with primary tumor(s) ≥ 1.0 cm on mammogram, ultrasound, mri, or physical exam * 18 years of age or older * subject must understand risks and benefits of the protocol and be able to give informed consent * females of child-bearing potential must agree to use an approved form of birth control and to have a negative pregnancy test result before and throughout the study * eastern cooperative oncology group (ecog) performance status of 0 or 1 * adequate hematologic and end organ function * ability and capacity to comply with the study and follow-up procedure * subjects must be scheduled for surgery at musc no less than 5 days from the planned start of day 1 and no more than 56 days from the planned start of day 1. * at least 6 sections of unstained slides should be obtained. if sufficient slides or tissue is unavailable, the patient will be excluded from the trial. exclusion criteria: * subjects undergoing neoadjuvant chemotherapy or neoadjuvant endocrine therapy * subjects with end-stage kidney disease and/or grade ii liver dysfunction * subject has active or history of deep vein thrombosis (dvt) * subject has a history of coagulopathies or hematological disorders * subjects who are pregnant or are lactating. * subjects already taking drugs known to be 5-lipoxygenase inhibitors (refer to section 5) * subjects taking drugs that interact with oatp1b3 (an anion transporter), mrp2 (a multidrug resistant protein), and/or p-glycoprotein (p-gp) (refer to section 5.) * subjects taking anti-coagulants or platelet inhibitors (refer to section 5) * subjects with bowel obstruction * subjects undergoing emergency surgery.
assessment of patient frailty prior to thoracic surgery

Conditions: Lung Cancer; Esophageal Cancer

Summary: determine the feasibility of assessment of measures of frailty and determine if these measures provide a clinically important contribution of risk assessment in a population of patients undergoing major thoracic surgery for lung or esophageal cancer.

both gastro-esophageal and lung cancers are major causes of morbidity and mortality worldwide. in canada the incidence for esophageal adenocarcinoma has doubled in the last two decades, while lung cancer is the leading cause of cancer death. surgery is a treatment option for these patients; however, esophagectomy in particular, is associated with significant morbidity, mortality and adverse effect on quality of life. despite satisfactory standard preoperative testing to evaluate risk for surgery, some patients experience morbidity and never recover fully from surgery. frailty assessment may offer a more sensitive measure of a patient's physiologic reserve, which may allow identification of patients who are poor candidates for surgery. there is a lack of consensus of how best to assess frailty prior to surgery. this study aims to analyze frailty assessment as a tool for patient selection for surgery.

Eligibility criteria:
inclusion criteria: * patients with esophageal or lung cancer who will undergo resectional surgery. exclusion criteria: * patients undergoing diagnostic or staging procedures or pulmonary wedge excisions will be excluded. * patients unable to give informed consent
effect of single dose intranasal insulin on cognitive function

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: the purpose of the study is to find out how a small dose of insulin might affect memory, the ability to concentrate, and improve your daily functioning in patients with schizophrenia and schizoaffective disorders. insulin is not being used to treat diabetes in this study. the investigators propose a single dose, double-blinded, placebo-controlled trial of intranasal insulin in 40 subjects with schizophrenia or schizoaffective disorder to examine insulin's effect on cognition. the specific aims include: 1. examine the effects of single doses of 40 iu intranasal insulin compared to placebo on cognitive functioning, including attention and memory. 2. examine whether single dose of intranasal insulin administration will raise serum insulin level and decrease plasma glucose level insulin will be delivered through an air spray pump into your nose. the investigators will be comparing one dose of insulin (40 international units) with placebo, an inactive liquid.

insulin signaling in the brain is associated with improved cognitive function in both animal and human studies. intranasal administration of insulin, which is non-invasive and minimizes the risk of hypoglycemia, may represent a new intervention approach with the potential to improve cognition and real life functioning in this patient with schizophrenia.

Eligibility criteria:
inclusion criteria: * age 18-65 years * diagnosis of schizophrenia, any subtype or schizoaffective disorder, any subtype * male or female * stable dose of the current antipsychotic drug for at least one month * well established compliance with out-patient treatment per treating clinician's judgement. * able to complete the cognitive assessment battery (must be english speaking) exclusion criteria: * inability to provide informed consent * current substance abuse * on clozapine or olanzapine * psychiatrically unstable per treating clinician's judgement. * significant medical illnesses including uncontrolled hypertension, diabetes, seizure disorder, severe cardiovascular, cerebrovascular, pulmonary, or thyroid diseases etc. * incapable to complete the cognitive battery assessment.

Keywords: schizophrenia memory concentration insulin
safety and feasibility of combined trigeminal and occipital transcutaneous nerve stimulation (cto-tns) in major depressive disorder (mdd)

Conditions: Major Depressive Disorder

Summary: safety and feasibility of combined trigeminal and occipital transcutaneous nerve stimulation (cto-tns) in major depressive disorder (mdd)


Eligibility criteria:
inclusion criteria: * the subject is capable of understanding the study and to sign an informed consent. * subject is between the ages of 18 to 65 years old. * unipolar major depressive disorder * score on the hamilton depression rating scale (hdrs21) \> 22 * current mdd episode \>3 months * nonresponse with \>6 week use of one to six antidepressant in current episode exclusion criteria: * history of neurosurgical interventions. * subjects with metal implants or shrapnel in their head, except for dental implants. * skin lesion or inflammation at the region of the stimulating electrodes. * pregnancy or lactation. * women of reproductive age not using efficient contraceptive method. * history of cerebrovascular event. * psychotic or bipolar depression * history of schizophrenia, schizoaffective disorder or other non-mood disorder psychosis * current delirium, dementia, amnestic disorder or other cognitive disorders * clinically significant current suicidal intent as assessed by the investigator team. * obsessive-compulsive disorder or post-traumatic stress disorder * alcohol and non-alcohol psychoactive substance abuse or dependence * significant cardiac, medical, or progressive neurological or medical illness * an implantable electrical device such as a pacemaker.
the role of intravitreal glucose in macular thinning following surgery for retinal detachment or epimacular membrane

Conditions: Vitrectomy; Macular Thinning

Summary: comparison between intravitreous glucose rate and macular thinning measured by ocular coherence tomography (oct) at 3 months post vitrectomy for retinal detachment or epimacular membrane. hypothesis : association between post-operative macular thickness and intravitreous glucose rate

comparison between intravitreous glucose rate and macular thinning measured by oct at 3 months post vitrectomy for retinal detachment or epimacular membrane. the cohort is divided in 2 groups, one with the thinnest macular measurement under 190µm, and the others above 190µm. we are looking for a correlation between increasing glucose rates and decreased macular thickness.

Eligibility criteria:
inclusion criteria: * patient who underwent vitrectomy for retinal detachment or epimacular membrane exclusion criteria: * patient suffering of diabetes, * recurrence of retinal detachment, * age-related macular degeneration, * post surgical macular oedema

Keywords: vitrectomy, macular thinning, retinal detachment, epimacular membrane, intravitreal glucose, oct